Skip to main content
AMGN
NASDAQ Life Sciences

Amgen's Repatha Slashes Cardiovascular Event Risk by 31% in High-Risk Patients

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$349.62
Mkt Cap
$188.011B
52W Low
$261.43
52W High
$391.29
52W Position info
34% above low
Off High info
11% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

AMGN sits 34% above its 52-week low of $261.43.

Summary

Amgen announced highly positive Phase 3 VESALIUS-CV clinical trial results for its drug Repatha, demonstrating a significant 31% reduction in the risk of a first major cardiovascular event, including heart attack, coronary heart disease death, and ischemic stroke, in high-risk patients. This new data is particularly impactful as it applies to patients without known significant atherosclerosis, potentially broadening the drug's addressable market. These strong efficacy results are a material positive for Amgen, strengthening its cardiovascular franchise and indicating a substantial opportunity for increased sales and market share for a key product. Investors will now closely monitor regulatory submissions for label expansion and the subsequent commercial rollout, which could significantly boost Amgen's long-term revenue outlook.

At the time of this announcement, AMGN was trading at $349.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $188B. The 52-week trading range was $261.43 to $391.29. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

AMGN - Latest Insights

AMGN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $477.40
Real-time Price: $465.00 info
Change: -$12.40 (-3%) info
Market Cap: $251.886B info
AMGN
Nov 03, 2026, 6:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $464.92
Real-time Price: $465.00 info
Change: +$0.080 (+0.02%) info
Market Cap: $251.886B info
AMGN
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $463.00
Real-time Price: $465.00 info
Change: +$2.00 (+0.43%) info
Market Cap: $251.886B info
AMGN
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.57
Real-time Price: $465.00 info
Change: +$4.43 (+0.96%) info
Market Cap: $251.886B info
AMGN
Oct 26, 2026, 9:23 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $448.79
Real-time Price: $465.00 info
Change: +$16.21 (+4%) info
Market Cap: $251.886B info